Small Molecules
5 December 2013
EFFECTIVENESS OF MARINOMED’S ANTIVIRAL NASAL SPRAY CONFIRMED IN CLINICAL TRIAL FOR COMMON COLD5 December 2013
Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder4 December 2013
3-V Biosciences Commences Patient Dosing in Phase 1 Clinical Study of FASN Inhibitor TVB-2640 in Patients with Advanced Solid Tumors4 December 2013
ARCA biopharma Announces US FDA Acceptance of Gencaro IND Application for the Treatment of Atrial Fibrillation4 December 2013
ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis4 December 2013
Galapagos reports positive Phase 1 results for GLPG12053 December 2013
Lexicon Completes Phase 2 Study Of LX1033 In IBS-d3 December 2013
Medivation and Astellas Initiate Phase 3 Study of Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer3 December 2013
Navidea Biopharmaceuticals Initiates Pivotal Phase 3 Registration Program of NAV5001 SPECT Imaging Agent for Parkinson’s Disease2 December 2013
Soligenix Announces Initiation of a Phase 2 Clinical Trial of orBec® for the Treatment of Chronic GI GVHD29 November 2013
New Data Show Efficacy, Safety and Tolerability of Xeplion® in Patients with Schizophrenia at Various Stages of the Disease28 November 2013
Velphoro(R) (PA21) receives US FDA approval28 November 2013
New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle27 November 2013
Galapagos announces GSK2586184 JAK1 molecule moves into Phase 2 for ulcerative colitis26 November 2013
FDA Approves Varithena™ (Polidocanol Injectable Foam) for the Treatment of Patients with Varicose Veins26 November 2013
ImStar Therapeutics Selects Lead Drug Candidate for ALS26 November 2013
Hepatitis C: Boehringer Ingelheim’s faldaprevir granted accelerated assessment from European Medicines Agency25 November 2013
NewGen Therapeutics Reports Potent Anticancer Activity for Targeted Brain Cancer Drug, NT-11325 November 2013
Ventrus Biosciences Completes Enrollment of Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients With Anal Fissure25 November 2013
RedHill Biopharma Announces First Patient Dosed in Phase III Study of RHB-104 for Crohn’s DiseaseNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports